MAR002 is an early, promising development: a new take on a proven strategy, with the potential for stronger IGF-1 control and dramatically less frequent dosing. At the same time, it’s important to keep expectations grounded. The drug is still investigational. It is not approved, not yet available outside clinical trials, and a larger patient study is needed to confirm what the early data suggest.
How should clinicians define disease control, select therapy, and personalize treatment for people living with acromegaly? A new three-part podcast series from The Pituitary Society explores these questions through the lens of the updated international consensus recommendations on therapeutic outcomes in acromegaly (Melmed S et al. Nat Rev Endocrinol 2025;21:718–37).
After years of clinical suspicion, large studies confirm elevated risk across multiple cancers From Lewis S Blevins Jr., MD – Professor of Neurological Surgery, Medical Director of the California Center for Pituitary Disorders at UCSF
HYPOTHALAMIC OBESITY: HOW TO HELP THE FIGHT AGAINST HUNGER-PROMOTING, EVOLUTIONARILY CONSERVED BRAIN NETWORKS From Francesca Galbiati, MD, neuroendocrinologist and neuroscientist, Assistant Professor medicine UCSF, and PWN contributing author – Tumors, surgery, traumatic brain injury, and
This book provides detailed reviews of several other pituitary conditions. While some were mentioned in previous books, this represents a deep dive into the world of neuroendocrine practice.
In this recent Medscape InDiscussion podcast Dr. Marwah Abdalla welcomes PWN’s Dr. Lewis Blevins to talk about secondary hypertension. This episode focuses on Cushing syndrome, an often overlooked cause of secondary hypertension. We’ll discuss why
In the latest episode of the Pituitary World News podcast, Jorge D. Faccinetti sits down with Dr. Markus Johnsson, Senior VP of R&D at Camurus, to explore the fascinating world of FluidCrystal® technology. This innovative approach promises to revolutionize the way we think about drug delivery, providing long-lasting solutions for chronic diseases particularly for people with acromegaly.
Crinetics announced today that the FDA has approved PALSONIFY™, the first once-daily oral therapy to treat acromegaly. The company announced the drug will be available in early October.
An Opinion Editorial from Jorge D. Faccinetti – Co-founder and Chief Editor – In today’s publishing landscape, one thing is clear: artificial intelligence and machine learning are advancing at dizzying speeds. Keeping up with these developments and understanding their true impact on our work and lives has become increasingly challenging.
Can Artificial Intelligence make medical research easier to understand? This is a fascinating question that we grapple with daily as we navigate the reality of an AI-driven publishing landscape. We’ll have more to say on this subject in the future, but for now, we want to share an AI-generated output in the form of a podcast, completely created by artificial intelligence, including all voices, tonality, and content. Even the visual representations of the two podcasters aren’t real. These people don’t exist. Ponder the implication of that notion for a while.